Ruhnn to Participate in Upcoming September Investor Conferences
HANGZHOU, China, Sept. 17, 2020 (GLOBE NEWSWIRE) — Ruhnn Holding Limited (“ruhnn” or the “Company”) (NASDAQ: RUHN), a leading internet […]
BioNTech to Acquire GMP Manufacturing Site to Expand COVID-19 Vaccine Production Capacity in First Half 2021
Mainz, Germany, Sept. 17, 2020 (GLOBE NEWSWIRE) —Facility will become one of the largest mRNA manufacturing sites in Europe and […]
New Data from Ciforadenant Phase 1b/2 Clinical Study Presented at ESMO Virtual Congress 2020
Data is part of Genentech’s MORPHEUS umbrella program and covers patients with resistant/refractory NSCLC treated with ciforadenant in combination with […]
Genocea Presents Follow-up Data from GEN-009 Neoantigen Vaccine Phase 1/2a Trial at ESMO Virtual Congress 2020
Step-down responses to GEN-009, with 3 objective responses (2 PR, 1 CR) in the first 5 patients, suggests added benefit […]
DZS and Tektraco Transform Malta with Hyper-Connected, Gigabit-Ready Projects
PLANO, Texas, Sept. 16, 2020 (GLOBE NEWSWIRE) — DZS (NSDQ: DZSI), a global provider of fixed and mobile packet, optical […]
Verona Pharma to Ring the Nasdaq Closing Bell to celebrate $200 million financing
LONDON and RALEIGH, N.C., Sept. 17, 2020 (GLOBE NEWSWIRE) — Verona Pharma plc (AIM: VRP) (Nasdaq: VRNA) (“Verona Pharma”), a […]
Forterra Announces Pricing of Secondary Offering of 10,000,000 Shares
IRVING, Texas, Sept. 16, 2020 (GLOBE NEWSWIRE) — Forterra, Inc. (the “Company” or “Forterra”) (NASDAQ: FRTA) announced today the pricing […]
Strongbridge Biopharma plc Announces Pricing of Public Offering of Ordinary Shares
DUBLIN, Ireland and TREVOSE, Pa., Sept. 16, 2020 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical […]
Sumo Logic Announces Pricing of Initial Public Offering
REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) — Sumo Logic, Inc. (“Sumo Logic”) today announced the pricing of its […]
Sorrento Receives US FDA Clearance to Proceed With Phase 1 Clinical Trial of STI-1499 (COVI-GUARD) Neutralizing Antibody in COVID-19 Positive Patients
Phase 1 clinical trial for STI-1499 (COVI-GUARD™) in hospitalized COVID-19 patients has received FDA notice that it may proceed with […]
